



**Contact:** Ralph Barry, Chief Business Officer  
Aegis Therapeutics LLC  
1-858-618-1400 Ext. 102  
Email: [rbarry@aegisthera.com](mailto:rbarry@aegisthera.com)

## **Aegis Therapeutics Invited to Present at the Health Care Ventures 2005 Conference**

SAN DIEGO, CA July 18, 2005/BusinessWire/-- Aegis Therapeutics LLC will be presenting at the Health Care Ventures 2005 Conference, sponsored by Dow Jones VentureWire. Dr. Edward T. Maggio, Ph.D., President and Chief Executive Officer, will provide a corporate overview, including a review of the Company's patented Intravail™ technology for intranasal and transmucosal delivery of peptide, protein, and non-protein macromolecular therapeutics, on Wednesday, Sept. 28 at 9:45 AM at the Sofitel San Francisco Bay, Redwood City, CA.

The conference will include CEOs from 60 companies in the most competitive sectors—including diabetes, obesity, oncology, neurology, personalized medicine, orthopedics, and eye disorders. Additional information on the conference may be found on the internet at the conference website: <http://healthcare-ventures.net/default.asp>

### **About Aegis Therapeutics**

Aegis Therapeutics LLC is a specialty pharmaceutical company commercializing its patented Intravail™ drug delivery technology that enables the non-invasive delivery of a broad range of protein, peptide and non-peptide macromolecular therapeutics that can currently only be administered by injection. Aegis' Intravail™ absorption enhancement agents are mild and non-irritating to mucosal membranes. They provide exceptionally high and unmatched bioavailability performance, comparable in efficiency to subcutaneous injection, via the intranasal and other mucosal membrane administration routes. Intravail™ also provides for rapid drug absorption and onset of action, controlled transient permeation of the nasal mucosal barrier, avoidance of gastric hydrolysis and "first pass effect" elimination by the liver, greater patient convenience and compliance, elimination of needle-stick injuries and associated transmission of blood borne pathogens, compatibility with current nasal delivery devices, and ease of formulation, scale-up, and production. For more information about Aegis, please visit the Aegis website at: <http://www.aegisthera.com>.

###